Treatment Algorithm for Metastatic Kidney Cancer

Opinion
Video

The Oncology Brothers and Sumanta Kumar Pal, MD, FASCO, offer comprehensive insights on the treatment of patients with metastatic kidney cancer.

Recent Videos
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Related Content
LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Belzutifan Receives European Approval in Localized/Advanced RCC Indications

Roman Fabbricatore
February 18th 2025
Article

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

Ariana Pelosci
February 15th 2025
Article

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Highlighting Advocacy Impacts on Funding for Kidney Cancer Research

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 16th 2024
Podcast

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

Lenvatinib/Belzutifan Exhibits Durable Antitumor Activity/Safety in ccRCC

Roman Fabbricatore
February 15th 2025
Article

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.

Investigators of a phase 2 study will continue to assess long-term efficacy and quality-of-life outcomes in those who receive lenvatinib/pembrolizumab.

Perioperative Lenvatinib Combo Shows Activity in Advanced Clear Cell RCC

Russ Conroy
February 15th 2025
Article

Investigators of a phase 2 study will continue to assess long-term efficacy and quality-of-life outcomes in those who receive lenvatinib/pembrolizumab.